• Voice Articles

    Perceived Needs, Preparedness, and Emotional Distress of Male Caregivers of Postsurgical Women With Gynecologic Cancer
  • Voice Articles

    My Personal Journey With Ovarian Cancer Treatment: Caring and Chemotherapy Tips
  • Drug Education

    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv

    In clinical trials, 24% of patients achieved an objective response rate with tisotumab vedotin-tftv (TivdakTM) that lasted a median of 8.3 months, leading to the agent’s U.S. Food and Drug Administration September 2021 approval for use in adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
  • Voice Articles

    Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review
  • Voice Articles

    PARP Inhibitors and Ovarian Cancer

    Before poly (adenosine diphosphate-ribose) polymerase inhibitors were approved for ovarian cancer, traditional treatment consisted of surgical cytoreduction and platinum-based chemotherapy with a taxane, with or without bevacizumab, depending on stage and type. With the surgery-chemotherapy combination, 70%–75% of patients had recurrence and overall five-year survival rate were 29%, indicating a need for additional therapies.

  • Voice Articles

    More Patients Are Skipping Their Cervical Cancer Screenings

    Nearly a quarter of patients who are eligible for cervical cancer screening are overdue for their current tests, researchers said in study findings published in JAMA Network Open. The number grew nearly 10% since 2005—representing a steady increase in missed screening over time—and was higher in different sociodemographic groups because of factors related to social determinants of health.
  • Voice Articles

    Caregiver Burden in End-Stage Ovarian Cancer
  • Voice Articles

    HPV Literacy: The Role of English Proficiency in Korean American Immigrant Women
  • Voice Articles

    Nursing Considerations for Ovarian Cancer Survivorship Care

    Historically, ovarian cancer is often diagnosed at advanced stages because of vague symptoms and presentation, but with new advancements in diagnosis and treatment options, patients with the disease are living longer than ever.